Andecaliximab

Monoclonal antibody

Phase 2/3underway

Evidence outlook · registrational

Fibrodysplasia Ossificans Progressiva: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-02-04.

Development in Rheumatoid Arthritis stopped (2017-08-07) as a strategic decision by the sponsor. Development continues in another indication. Source

Development in Ulcerative Colitis stopped as a strategic decision by the sponsor. Development continues in another indication. Source

Development in Crohn's Disease stopped as a strategic decision by the sponsor. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Other / comorbidity
NCT02545504 · Gilead Sciences
2015-10-13 – 2019-05-15 · Gastric Adenocarcinoma
What this study did
Phase 2/3 (2)
Fibrodysplasia Ossificans Progressiva
Other / comorbidity
Phase 2 (4)
Other / comorbidity
NCT02864381 · Gilead Sciences
2016-09-01 – 2019-08-23 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02759562 · Gilead Sciences
2016-11-04 – 2017-07-21 · Cystic Fibrosis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07024407 · Ashibio Inc
2025-05-14 – 2029-01 · Heterotopic Ossification (HO)
What this study did
Phase 1 (6)
Other / comorbidity
NCT01803282 · Gilead Sciences
2013-03-29 – 2019-04-23 · Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
What this study did
NCT02176876 · Gilead Sciences
2014-08 – 2015-06 · Rheumatoid Arthritis
What this study did
NCT02077465 · Gilead Sciences
2014-03-11 – 2014-10-27 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02209987 · Gilead Sciences
2014-08 – 2014-10 · Ulcerative Colitis
What this study did

Competitive landscape

This drug's own stage for Fibrodysplasia Ossificans Progressiva: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Andecaliximab: this drugPhase 2/3Monoclonal antibodyMatrix metalloproteinase-9 (MMP-9)not yet gradedNo reviewed efficacy summary in this indication
Garetosmab (Pasatru)ApprovedMonoclonal antibodyActivin AReliable signal
NCT05394116: OPTIMA (NCT05394116), primary endpoint new HO lesions by whole-body CT at week 56: 94% reduction with garetosmab 3 mg/kg vs placebo; 90% reduction with garetosmab 10 mg/kg vs placebo

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Andecaliximab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
Phase 1/2Heterotopic Ossification (HO)Active not recruiting
Est. primary completion 2028-12 · NCT07024407 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2/3Fibrodysplasia Ossificans ProgressivaActive not recruiting
Est. primary completion 2029-02-04 · NCT06508021 · CT.gov ↗
What to watch

See the full readout calendar ↗